PRT-2527

N/A

Report date: 2026/05/28 20:00:21
NME

Base Information

Drug NamePRT-2527
Drug Alias NamePRT-2527
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 9 inhibitors
TargetsCyclin-dependent kinase 9
Therapy Area/IndicationsSolid tumoursRichter's SyndromeMyelodysplastic Syndromes +[16] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPoland +[10] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPrelude Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesPrelude Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursRichter's SyndromeMyelodysplastic Syndromes +[16] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A